| A controlled trial of Natalizumab for relapsing multiple sclerosis DH Miller, OA Khan, WA Sheremata, LD Blumhardt, GP Rice, MA Libonati, ... New England Journal of Medicine 348 (1), 15-23, 2003 | 1585 | 2003 |
| Achieving saturation in thematic analysis: Development and refinement of a codebook H Ando, R Cousins, C Young Comprehensive Psychology 3 (Article 4), 2014 | 877 | 2014 |
| Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis DJ Rog, TJ Nurmikko, T Friede, CA Young Neurology 65 (6), 812-819, 2005 | 864 | 2005 |
| Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind … G Comi, V Martinelli, M Rodegher, L Moiola, O Bajenaru, A Carra, ... The Lancet 374 (9700), 1503-1511, 2009 | 799 | 2009 |
| Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta ... Neurology 56 (11), 1496-1504, 2001 | 504 | 2001 |
| Placebo-controlled trial of oral laquinimod for multiple sclerosis FM Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, ... New England journal of medicine 366 (11), 1000-9, 2012 | 447 | 2012 |
| The effect of anti-α4 integrin antibody on brain lesion activity in MS N Tubridy, PO Behan, R Capildeo, A Chaudhuri, R Forbes, CP Hawkins, ... Neurology 53 (3), 466-466, 1999 | 417 | 1999 |
| Anti‐spasticity agents for multiple sclerosis D Shakespeare, M Boggild, CA Young, ... Cochrane Database of Systematic Reviews 2010 (1), 1996 | 409 | 1996 |
| Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open … R Kapoor, PR Ho, N Campbell, I Chang, A Deykin, F Forrestal, N Lucas, ... The Lancet Neurology 17 (5), 405-415, 2018 | 371 | 2018 |
| Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled … G Comi, A Pulizzi, M Rovaris, O Abramsky, T Arbizu, A Boiko, R Gold, ... Lancet 371 (9630), 2085-92, 2008 | 353 | 2008 |
| Treatment with laquinimod reduces development of active MRI lesions in relapsing MS LRMSSG Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T Neurology 64 (6), 987-991, 2005 | 310 | 2005 |
| Oromucosal Δ9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial DJ Rog, TJ Nurmikko, CA Young Clinical therapeutics 29 (9), 2068-2079, 2007 | 298 | 2007 |
| Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P ... J Neurol Neurosurg Psychiatry 87 (2), 117-25, 2016 | 278 | 2016 |
| Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis N Scolding, D Barnes, S Cader, J Chataway, A Chaudhuri, A Coles, ... Practical neurology 15 (4), 273-279, 2015 | 275 | 2015 |
| A medical definition of fatigue in multiple sclerosis RJ Mills, CA Young QJM: An International Journal of Medicine 101 (1), 49-60, 2008 | 245 | 2008 |
| Treatment for ataxia in multiple sclerosis RJ Mills, L Yap, CA Young Cochrane Database of Systematic Reviews, 2007 | 202 | 2007 |
| Perceptions of self-efficacy and rehabilitation among neurologically disabled adults G Dixon, EW Thornton, CA Young Clinical rehabilitation 21 (3), 230-240, 2007 | 186 | 2007 |
| A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment J Craig, CA Young, M Ennis, G Baker, M Boggild Journal of Neurology, Neurosurgery & Psychiatry 74 (9), 1225-1230, 2003 | 178 | 2003 |
| Quality of life in multiple sclerosis in France, Germany, and the United Kingdom N Murphy, C Confavreux, J Haas, N König, E Roullet, M Sailer, M Swash, ... Journal of neurology, neurosurgery & psychiatry 65 (4), 460-466, 1998 | 172 | 1998 |
| A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS MS Freedman, A Bar-Or, J Oger, A Traboulsee, D Patry, C Young, ... Neurology 77 (16), 1551-1560, 2011 | 153 | 2011 |
Alan TennantLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK.Email được xác minh tại leeds.ac.uk